SYENS SYENSQO

Participatiemelding van BlackRock Inc.

Participatiemelding van BlackRock Inc.

Participatiemelding van BlackRock Inc.

Brussel, België - 2 Mai 2024 – 8u30 CEST

In overeenstemming met de Belgische wetgeving op de openbaring van belangrijke deelnemingen (wet van 2 mei 2007), heeft BlackRock Inc. (50 Hudson Yards, New York, NY, 10001, U.S.A.) een transparantiemelding naar Syensqo gestuurd om aan te geven dat de drempel van 3% is overschreden. Hier is een samenvatting van de beweging:

Datum van drempeloverschrijding Stemrechten na de transactie Aan stemrechten gelijkgestelde financiële instrumenten na de transactie Totaal
25 april 2024 2.99% 0.67% 3.67%

De kennisgeving van 29 april 2024 bevat de volgende informatie:

  • Reden van de kennisgeving: Verwerving of overdracht van stemrechtverlenende effecten of stemrechten
  • Kennisgeving door: BlackRock Inc. (50 Hudson Yards, New York, NY, 10001, U.S.A.)
  • Datum van drempeloverschrijding: 25 april 2024
  • Overschreden drempel van directe stemrechten: 3% neerwaarts
  • Noemer: 105 876 416
  • Toegevoegde informatie: de informatieverplichting ontstond doordat stemrechten verbonden aan aandelen voor BlackRock, Inc. onder de 3% daalden.
  • Kennisgeving Plichtige personen: zie bijgevoegd bestand

De verklaringen en de volledige keten van gecontroleerde ondernemingen waardoor het bedrijf feitelijk wordt aangehouden, is beschikbaar in de op de website van Syensqo.

Media relations



 









 



Nathalye Van Ypersele

2



 



Perrine Marchal

2



 



Laetitia Schreiber

7
Investor Relations



 









 



Sherief Bakr

9



 



Bisser Alexandrov

80



 



Imtiyaz Lokhandwala

 

Bijlages



EN
02/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYENSQO

 PRESS RELEASE

Syensqo - Acquisition of own shares

Syensqo - Acquisition of own shares Regulated Acquisition of own shares  Brussels, October 20, 2025 - 17:45 CET In accordance with article 7:215 of the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) pursues its Share Buyback Program (or the “Program”) announced on September 30, 2024, covering up to €300 million. The fourth tranche began on July 31, 2025 and will cover a maximum amount of up to €50 million (of the €300 million Program). The Company intends to cancel all shares acquired through this tranche.  In the framework of this tran...

 PRESS RELEASE

Syensqo - Participation notification by Capital Group Companies Inc.

Syensqo - Participation notification by Capital Group Companies Inc. Regulated Participation notification by Capital Group Companies Inc. Brussels, Belgium – October 14, 2025 - 8:30 CEST According to Belgian transparency legislation (Law of May 2, 2007), The Capital Group Companies, Inc. (333 South Hope Street 55fl. Los Angeles, CA 90071) recently sent Syensqo the following transparency notifications indicating that it crossed the threshold of 3%. Here is the summary of the moves: Date on which the threshold was crossed Voting rights after the transaction Equival...

 PRESS RELEASE

Syensqo - Acquisition of own shares

Syensqo - Acquisition of own shares Regulated Acquisition of own shares  Brussels, October 13, 2025 - 17:45 CET In accordance with article 7:215 of the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) pursues its Share Buyback Program (or the “Program”) announced on September 30, 2024, covering up to €300 million. The fourth tranche began on July 31, 2025 and will cover a maximum amount of up to €50 million (of the €300 million Program). The Company intends to cancel all shares acquired through this tranche.  In the framework of thi...

Guy Sips ... (+4)
  • Guy Sips
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASML: Chinese advanced DUV machine on trial; Azelis: Muddling through 2025 PostNL: CMD - new strategy and ambitions for 2028; Proximus: New CEO of Proximus Global announced Syensqo: CEO succession; UCB: Brivekimig (Sanofi) P2a results in Hidradenitis Suppurativa

ResearchPool Subscriptions

Get the most out of your insights

Get in touch